Combination of hdac inhibitors with thrombocytopenia drugs
AssigneeNovartis AG
InventorsPeter Wisdom Atadja, Ricky Wayne Johnstone, Henry Miles Prince, Mark John Brishton, Simon James Harrison
Life of this patent
Estimating the term…
Abstract
The invention relates to a combination which comprises: (a) a HDAC inhibitor; and (b) an anti-thrombocytopenia drug, for simultaneous, concurrent, separate or sequential use, especially for use in the treatment of a proliferative diseases. The invention also relates to pharmaceutical compositions or products comprising such a combination, or a method using such a combination
Claims12
The combination of (a) N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide, or a pharmaceutically acceptable salt thereof in combination with (b) an anti-thrombocytopenia drug.
The combination of:
- (a) an HDACi inhibitor selected from the group consisting of panobinostat, romidepsin, vorinostat, and combinations thereof;
- (b) an anti-TCP drug selected from the group consisting of eltrombopag, romiplostim, or both;
- and, optionally,
- (c) an anti-metabolite selected from the group consisting of 5-azacytidine, decitabine, or both.
Dependencies are inferred from the claim text.